Grant funding awarded to support lupus-focused community programs across the United States
With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.
Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer treatment, with...
The United States and the United Kingdom have reached an agreement in principle on pharmaceutical pricing as part of the new U.S.–U.K. Economic Prosperity Deal, aimed at addressing long-standing pricing...
Significant unmet need for patients requires new and novel treatments 1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free...
Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment 1 Data will be...
GlaxoSmithKline ((GSK)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data,...
GlaxoSmithKline ((GSK)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data,...
GlaxoSmithKline ((GSK)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data,...